美国血液学会2020年镰状细胞病指南:输血支持
美国血液学会组织多学科专家组,采用GRADE方法制定镰状细胞病输血支持指南,围绕红细胞抗原分型与匹配、输血指征与方式(简单输血对比红细胞置换)、同种免疫筛查预防管理、迟发性溶血性输血反应及铁过载管理共形成10条推荐,多数为条件性推荐,因直接高确定性证据缺乏。
要点
- 指南针对镰状细胞病输血支持及输血相关并发症管理提出10条推荐。
- 推荐覆盖红细胞抗原分型匹配、输血指征与方式、同种免疫和铁过载管理。
- 多数推荐为条件性,因缺乏直接高确定性证据。
核心结论
- 专家组共形成10条推荐,聚焦红细胞抗原分型与匹配、输血指征与给药方式以及同种免疫、迟发性溶血性输血反应和铁过载的筛查、预防与管理。
- 多数推荐为条件性推荐,原因是针对感兴趣结局的直接高确定性证据匮乏。
研究设计与样本
- 美国血液学会组建了多学科专家组,成员平衡以减少利益冲突偏倚,并包含一名患者代表。
- 专家组优先确定临床问题与结局,由Mayo Clinic循证实践研究项目支持指南制定过程。
- 采用推荐分级的评估、制定与评价(GRADE)方法形成推荐,并经过公开评论。
主要发现
- 指南共形成10条推荐,覆盖红细胞抗原分型与匹配、输血指征、给药方式(简单输血对比红细胞置换)以及同种免疫、迟发性溶血性输血反应和铁过载的筛查、预防与管理。
关键数值与推荐
- 推荐条款涉及红细胞抗原分型与匹配、输血指征与给药方式选择以及同种免疫、迟发性溶血性输血反应和铁过载的筛查、预防与管理。
临床怎么用
- 为患者、临床医生及其他医疗专业人员提供基于证据的指南,支持其在镰状细胞病输血支持及输血相关并发症管理中的决策。
局限性
- 多数推荐为条件性推荐,因缺乏针对感兴趣结局的直接高确定性证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Red cell transfusions remain a mainstay of therapy for patients with sickle cell disease (SCD), but pose significant clinical challenges. Guidance for specific indications and administration of transfusion, as well as screening, prevention, and management of alloimmunization, delayed hemolytic transfusion reactions (DHTRs), and iron overload may improve outcomes. OBJECTIVE: Our objective was to develop evidence-based guidelines to support patients, clinicians, and other healthcare professionals in their decisions about transfusion support for SCD and the management of transfusion-related complications. METHODS: The American Society of Hematology formed a multidisciplinary panel that was balanced to minimize bias from conflicts of interest and that included a patient representative. The panel prioritized clinical questions and outcomes. The Mayo Clinic Evidence-Based Practice Research Program supported the guideline development process. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to form recommendations, which were subject to public comment. RESULTS: The panel developed 10 recommendations focused on red cell antigen typing and matching, indications, and mode of administration (simple vs red cell exchange), as well as screening, prevention, and management of alloimmunization, DHTRs, and iron overload. CONCLUSIONS: The majority of panel recommendations were conditional due to the paucity of direct, high-certainty evidence for outcomes of interest. Research priorities were identified, including prospective studies to understand the role of serologic vs genotypic red cell matching, the mechanism of HTRs resulting from specific alloantigens to inform therapy, the role and timing of regular transfusions during pregnancy for women, and the optimal treatment of transfusional iron overload in SCD.
引用
- Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020. PMID: 31985807. doi:10.1182/bloodadvances.2019001143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。